GLP Toxicology Studies

To assess toxicity, Medicilon offers a wide range of GLP and non-GLP toxicology services. GLP and non-GLP Toxicology studies are required to determine the adverse effects of drug candidates and the effect of dosage on toxicity.

glp toxicology study

Preclinical CRO / Toxicology Studies Include:

Late-Stage Discovery Studies

Pharmacokinetics Study (PK)
Maximum Tolerated Dose Studies (MTD)
Dose Range Finding Study
hERG - Ion Channel Screening
Exploratory Toxicology Study (7-day non-GLP Studies with PK)

GLP Toxicology Studies

7-day Repeat Dose Study (GLP)
14-day Repeat Dose Study (GLP)
21-day Repeat Dose Study (GLP)
3-month Chronic Repeat Dose Study (GLP)
6-month Chronic Repeat Dose Study (GLP)
9-month Chronic Repeat Dose Study (GLP)
Carcinogenicity Studies (Transgenic & 2 year)

Safety Pharmacology Studies (GLP)

Cardiovascular Study (Telemetry or Piggy-backed)
Respiratory Study
Central Nervous System Study (CNS Study)

Genetic Toxicology (Genetox)

Ames Assay (non-GLP & GLP) CRO
Micronucleus Assay
Chromosomal Aberration Assay

With extensive experience in drug development, Medicilon staff is dedicated to helping you complete your project in a timely and efficient manner. In addition to Good Laboratory Practice (GLP) toxicology studies, Medicilon provides all aspects of the GLP process from design to regulatory support of your IND FDA submission. Our preclinical team has extensive experience in set-up and management of GLP animal toxicology studies and other experience across all facets of preclinical research, from identification, assessment and due diligence on new compounds to conduct of animal models.

Contact Us

Email : marketing@medicilon.com

Tel : +86 021 5859-1500

Tips : Above is part of GLP Toxicology Studies, GLP Toxicology and Toxicology Testing Labs. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

New Drug Preclinical Toxicology Research

General Toxicology Study Service

Drug Safety Evaluation Center

Pharmacokinetic test / toxicokinetic test

Medicilon attended the 6th National Congress of Toxicology successfully in Guangzhou

Preclinical studies and clinical trials of drugs

Toxicokinetic Studies in Animals

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

On July 20, 2020, DAC Biotech’s new ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

Shanghai Medicilon Inc.

搜索此博客